Kayexalate

Sodium polystyrene sulfonate, the active ingredient in Kayexalate, is a cation exchange resin presented as an oral suspension/rectal enema for oral and rectal use. It treats hyperkalemia by binding potassium in the gastrointestinal tract, primarily in patients with elevated serum potassium levels.

GNH USA supplies Kayexalate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kayexalate is a potassium‑binding resin used in the management of disorders that cause elevated serum potassium.

- Hyperkalemia: lowers serum potassium concentrations in acute or chronic settings. - Acute hyperkalemia: provides rapid removal of excess potassium to prevent cardiac complications. - Chronic hyperkalemia: helps maintain potassium balance in patients with renal impairment or on potassium‑raising therapies.

Kayexalate may cause a range of adverse reactions, most of which are related to the gastrointestinal tract.

Common Side Effects: - Nausea: mild to moderate discomfort after ingestion. - Vomiting: occasional expulsion of stomach contents. - Constipation: reduced bowel movements, may require monitoring. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain in the abdomen. - Taste alteration: metallic or unpleasant taste.

Serious or Rare Side Effects: - Intestinal necrosis: rare but severe tissue death, especially with sorbitol. - Severe electrolyte imbalance: hypokalemia or hypernatremia requiring urgent care. - Colonic ulceration: ulcer formation in the colon. - Bowel obstruction: blockage due to severe constipation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Metabolic acidosis: rare disturbance of acid‑base balance.

Before initiating Kayexalate, clinicians should consider several safety measures.

- Monitor serum potassium: check levels before and during therapy. - Assess renal function: adjust use in patients with impaired kidney function. - Evaluate gastrointestinal status: avoid in patients with bowel obstruction or inflammatory bowel disease. - Use caution with ACE inhibitors or potassium‑sparing diuretics: risk of additive hyperkalemia. - Avoid concomitant sorbitol‑containing laxatives: increased risk of intestinal necrosis. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Kayexalate can interact with other medicines that affect potassium balance or gastrointestinal integrity.

Major Interactions (Avoid): - Sorbitol‑containing laxatives: may precipitate intestinal necrosis. - ACE inhibitors: can exacerbate hyperkalemia. - Potassium‑sparing diuretics: additive effect on potassium levels.

Moderate Interactions (Monitor Closely): - Digoxin: potassium shifts may alter digoxin toxicity. - Lithium: changes in electrolyte balance can affect lithium levels.